Patents by Inventor Barbara Hanney

Barbara Hanney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
    Patent number: 9663506
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: May 30, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
  • Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
    Patent number: 9636337
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: May 2, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
  • Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use
    Publication number: 20160158217
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
  • Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use
    Publication number: 20160159744
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
  • Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
    Patent number: 9278960
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher James Bungard, Antonella Converso, Barbara Hanney, Timothy John Hartingh, Peter J. Manley, Robert S. Meissner, James J. Perkins, Michael T. Rudd
  • Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
    Patent number: 9102673
    Abstract: The present invention is directed to compounds of formula I and Ia: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 11, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Barbara Hanney, Peter Manley, Michael T. Rudd, John M. Sanders, Shawn J. Stachel, Darrell Henze
  • QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
    Publication number: 20140309227
    Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
  • TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20140155413
    Abstract: The present invention is directed to compounds of formula I and 1a: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 5, 2014
    Inventors: Barbara Hanney, Peter Manley, Michael T. Rudd, John M. Sanders, Shawn J. Stachel, Darrell Henze
  • N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators
    Publication number: 20100267633
    Abstract: The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.
    Type: Application
    Filed: September 22, 2006
    Publication date: October 21, 2010
    Inventors: Barbara Hanney, Yuntae Kim, Helen J. Mitchell, Jeffrey D. Musselman, James J. Perkins
  • N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
    Patent number: 7763659
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 27, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • -(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
    Patent number: 7629367
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: December 8, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • Carbonylamino-benzimidazole derivatives as androgen receptor modulators
    Patent number: 7622592
    Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: November 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Yuntae Kim, Barbara Hanney, Mark E. Duggan, Keith L. Spencer
  • Substituted oxoazaheterocyclyl compounds
    Patent number: 7612075
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Michael R. Myers, Wan F. Lau, Aiwen Li, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Tyrosine Kinase Inhibitors
    Publication number: 20090149467
    Abstract: The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: September 11, 2006
    Publication date: June 11, 2009
    Applicant: MERCK & CO., INC.
    Inventors: Christopher J. Dinsmore, David J. Guerin, Barbara Hanney, Yuntae Kim, Keith L. Spencer, Maricel Torrent
  • N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
    Publication number: 20090088458
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Application
    Filed: July 28, 2006
    Publication date: April 2, 2009
    Inventors: Robert S. Meissner, James J. Perkins, Yuntae Kim, Barbara Hanney, Carol A. McVean
  • N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators
    Publication number: 20080139630
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Application
    Filed: June 3, 2005
    Publication date: June 12, 2008
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
    Publication number: 20080124402
    Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Application
    Filed: October 25, 2005
    Publication date: May 29, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Yuntae Kim, Joshua Close, Mark E. Duggan, Barbara Hanney, Robert S. Meissner, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
    Publication number: 20070225229
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 27, 2007
    Inventors: Barbara Hanney, Yuntae Kim, Michael Krout, Robert Meissner, Helen Mitchell, Jeffrey Musselman, James Perkins, Jiabing Wang
  • N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
    Patent number: 7268153
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: September 11, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • Tyrosine kinase inhibitors
    Patent number: 7186723
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: March 6, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer